Q2 FY2026 EarningsQ2 FY26 revenue of $47.3M missed the $49.1M consensus, while gross margin outperformed at 89% vs. 87% expected. The bottom line saw a significant miss, with a GAAP EPS of -$0.16 compared to the -$0.15 consensus and an Adjusted EBITDA loss of $3.5M. Management slashed full-year 2026 revenue guidance to $205.5M-$212.5M (well below the prior ~$225M mid-point) and lowered Adjusted EBITDA expectations to a range of -$6M to breakeven, signaling a more difficult transition from compounded to branded GLP-1 therapies.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: LifeMD(LFMD) the Revenue is 47.28 M (-24.01%), Miss estimate;the EBIT is -7.13 M (-686.3%), Miss estimate;the EPS is -0.16 (-166.7%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.05B24.01%
0.05B21.08%
-0.00B2.93%
EBITMiss expectations
-0.01B686.26%
-0.01B574.80%
-0.00B111.46%
EPSMiss expectations
-0.16166.67%
-0.1457142.85%
-0.014323.82%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf